Professor Nicola Dalbeth
MBChB MD FRACP
Nicola Dalbeth is an academic rheumatologist who leads a clinical and laboratory programme of research in gout, an inflammatory arthritis of major significance to Aotearoa/New Zealand. Her work focuses on understanding the impact and mechanisms of disease in gout.
She has served as a member of the Core Leadership Team on the American College of Rheumatology (ACR) Gout Management Guidelines, and as a steering committee member for the Outcome Measures in Rheumatology (OMERACT) gout group and the ACR/European League Against Rheumatism gout classification project.
Research | Current
Clinical research includes clinical trials, imaging studies (using plain radiographs, MRI and three-dimensional CT modeling) to analyze joint damage, studies to investigate the functional impact of gout, and validation of outcome measures in gout. The laboratory work in the Auckland Bone and Joint Research Laboratory involves investigating the cellular and molecular mechanisms of inflammation and joint damage in gout.
Selected publications and creative works (Research Outputs)
- FitzGerald, J. D., Dalbeth, N., Mikuls, T., Brignardello-Petersen, R., Guyatt, G., Abeles, A. M., ... King, C. (2020). 2020 American College of Rheumatology Guideline for the Management of Gout. ARTHRITIS CARE & RESEARCH10.1002/acr.24180
- FitzGerald, J. D., Dalbeth, N., Mikuls, T., Brignardello-Petersen, R., Guyatt, G., Abeles, A. M., ... King, C. (2020). 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis & rheumatology (Hoboken, N.J.)10.1002/art.41247
- Tai, V., Narang, R. K., Gamble, G., Cadzow, M., Stamp, L. K., Merriman, T. R., & Dalbeth, N. (2020). Do Serum Urate-Associated Genetic Variants Differentially Contribute to Gout Risk According to Body Mass Index? Analysis of the UK Biobank. ARTHRITIS & RHEUMATOLOGY10.1002/art.41219
- Gasteiger, C., Lobo, M., Dalbeth, N., & Petrie, K. J. (2020). Patients' beliefs and behaviours are associated with perceptions of safetyand concerns in a hypothetical biosimilar switch. Rheumatology international10.1007/s00296-020-04576-7
Other University of Auckland co-authors: Chiara Gasteiger, Keith Petrie
- Dalbeth, N., Douglas, M., MacKrill, K., Te Karu, L., Kleinstäuber M, & Petrie, K. J. (2020). The impact of the illness label 'gout' on illness and treatment perceptions in Māori (Indigenous New Zealanders). BMC Rheumatology, 4 (1).10.1186/s41927-020-00120-z
Other University of Auckland co-authors: Kate MacKrill, Keith Petrie
- Klück V, van Deuren, R. C., Cavalli, G., Shaukat, A., Arts, P., Cleophas, M. C., ... Dalbeth, N. (2020). Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout. Annals of the rheumatic diseases, 79 (4), 536-544. 10.1136/annrheumdis-2019-216233
- Keen, H. I., Robinson, P. C., Dalbeth, N., & Hill, C. (2020). Time to recognise gout as a chronic disease. The Medical journal of Australia, 212 (6), 285-285.e1. 10.5694/mja2.50512
- Stewart, S., Tallon, A., Taylor, W. J., Gaffo, A., & Dalbeth, N. (2020). How flare prevention outcomes are reported in gout studies: A systematic review and content analysis of randomized controlled trials. Seminars in arthritis and rheumatism, 50 (2), 303-313. 10.1016/j.semarthrit.2019.11.002
Other University of Auckland co-authors: Sarah Stewart